scholarly journals Treatment with Intramuscular Levothyroxine in Refractory Hypothyroidism

2019 ◽  
Vol 8 (6) ◽  
pp. 319-323 ◽  
Author(s):  
María de los Ángeles Garayalde Gamboa ◽  
Melina Saban ◽  
Marina Ines Curriá

Introduction: Orally and daily levothyroxine (LT4) is the treatment of choice for hypothyroidism. In the majority of cases, the lack of effectiveness by this way may be due to poor adherence; however, gastrointestinal malabsorption may explain more cases of thyroxine refractoriness than previously reputed, due to the number of occult forms of these disorders. Case Presentation: A 55-year-old white man with a diagnosis of low risk of recurrence of follicular variant of papillary thyroid carcinoma was treated with total thyroidectomy, 30 mCi iodine 131, and oral LT4. A year before he presented a gastric adenocarcinoma that required a partial gastrectomy. He evolved with multiple episodes of intestinal subocclusion that had to be treated with enterectomy in the first instance, then digestive rest and total parenteral nutrition. In spite of having made increases in oral LT4 dose (3 µg/kg), the patient persisted with a thyroid-stimulating hormone level >100 mIU/L. For this reason, we decided to administer intramuscular LT4. Conclusion: Since there are no guidelines or consensus of intramuscular LT4 use, our experience and how we decided the dose and way of administration are presented in this article to contribute to future cases.

2021 ◽  
Vol 2021 ◽  
pp. 1-8
Author(s):  
Somaya Safi ◽  
Yousra Benabdelfedil ◽  
Sara Derrou ◽  
Faycal El Guendouz

Background. The thyrotropin-secreting adenomas are very rare and even more rare when they simultaneously coexist with thyroid carcinoma. So far, only sixteen cases have been reported in the literature. Here, we present a unique case of successful management of a concurrent case of thyrotropin-prolactinoma with papillary thyroid carcinoma. Case Presentation. A 50-year-old Moroccan woman underwent a total thyroidectomy and complementary totalization by iratherapy for papillary thyroid carcinoma, who presented persistence of an inappropriate secretion of the thyroid-stimulating hormone (TSH > 4 mUI/L) despite of levothyroxine suppressive therapy (300 μg/d). After eliminating noncompliance, interfering medicines, and thyroid malabsorption, a pituitary adenoma (12 mm) was documented at magnetic resonance imaging. The patient has had transsphenoidal pituitary adenomectomy with histology confirming a thyrotropin-prolactin-secreting adenoma. After surgery and lanreotide treatment failures, we noted a complete response (TSH < 0.5) with cabergoline treatment (3 mg/week). Conclusion. The unusual association of thyroid adenocarcinoma and TSHoma enriches the hypothesis of a potential link between thyrotropic hypersecretion and thyroid carcinogenesis. Our case also illustrates the difficulty of monitoring thyroid carcinoma in nonremission of a TSHoma.


Author(s):  
Fernando Garcia Perez ◽  
Guillermo Martinez de Pinillos Gordillo ◽  
Mariana Tome Fernandez-Ladreda ◽  
Eyvee Arturo Cuellar Lloclla ◽  
Jose Alvaro Romero Porcel ◽  
...  

Thyroid ◽  
2005 ◽  
Vol 15 (12) ◽  
pp. 1349-1354 ◽  
Author(s):  
Tasoula Tsilchorozidou ◽  
Eleni Vafiadou ◽  
John G. Yovos ◽  
Giovani Romeo ◽  
James McKay ◽  
...  

2016 ◽  
Vol 107 (1) ◽  
pp. 83-85
Author(s):  
A. Márquez García ◽  
L. Ferrándiz Pulido ◽  
J.J. Ríos-Martín ◽  
F.M. Camacho Martínez

2018 ◽  
Vol 19 (3) ◽  
pp. 655 ◽  
Author(s):  
Marta Kotlarek ◽  
Anna Kubiak ◽  
Małgorzata Czetwertyńska ◽  
Michał Świerniak ◽  
Wojciech Gierlikowski ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document